Neuromyelitis Optica and Its Spectrum
D.M. Wingerchuk and C.F. Lucchinetti
Formerly known as Devic’s disease, this relapsing, demyelinating disorder of the central nervous system encompasses six syndromes and is associated with aquaporin-4 autoantibodies. Effective treatment prevents relapses.Aug 18
Images in Clinical Medicine
Combined Degeneration from Nitrous Oxide Use
J.Y. Yoon and J.P. Klein
A 32-year-old man with daily nitrous oxide inhalant use presented with an inability to walk. MRI of the whole spine revealed hyperintensities in the posterior spinal cord on T2-weighted images.Sep 01
- Review Article Neuromyelitis Optica and Its Spectrum D.M. Wingerchuk and C.F. Lucchinetti
Ublituximab vs. Teriflunomide in Multiple Sclerosis
L. Steinman and Others
In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability.Aug 25
- Original Article Ublituximab vs. Teriflunomide in Multiple Sclerosis L. Steinman and Others
Most Viewed in Neurology/Neurosurgery
Relative Afferent Pupillary Defect
S. Manjunathan and L. Saini
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
L. Steinman and Others
Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest
J. Kjaergaard and Others
Oxygen Targets in Comatose Survivors of Cardiac Arrest
H. Schmidt and Others
- N Engl J Med 2022; 387:832-832
A 32-year-old man with daily nitrous oxide inhalant use presented with an inability to walk. MRI of the whole spine revealed hyperintensities in the posterior spinal cord on T2-weighted images.
- Original ArticleAug 27, 202210.1056/NEJMoa2208686
In comatose patients after out-of-hospital cardiac arrest, the incidence of death or severe disability was similar regardless of whether a restrictive or a liberal oxygenation strategy was used.
- Original ArticleAug 27, 202210.1056/NEJMoa2208687
This trial showed no significant difference in the percentage of patients who died or had severe disability or coma when higher or lower blood-pressure targets were used after an out-of-hospital cardiac arrest.
- N Engl J Med 2022; 387:e15
A 13-year-old girl with blurry vision, painful eye movements, and weakness and paresthesias in her left leg was found to have a relative afferent pupillary defect in her left eye (shown in a video).
- N Engl J Med 2022; 387:704-714
- N Engl J Med 2022; 387:661-662
A patient in whom Japanese encephalitis was diagnosed in February 2021 has been identified as a likely sentinel human case of the 2022 outbreak of the disease in Australia.
- N Engl J Med 2022; 387:641-650
A 25-year-old woman was evaluated for worsening headaches, photophobia, nausea, vomiting, and blurred vision. MRI revealed hydrocephalus and leptomeningeal enhancement. CSF analysis revealed neutrophilic pleocytosis.
- N Engl J Med 2022; 387:631-639
- N Engl J Med 2022; 387:491-493
A shortage of contrast material has made weighing value an urgent aspect of imaging decisions and provided a stark example of the consequences of low-value imaging for public health and health equity.
- N Engl J Med 2022; 387:e9
This interactive feature describes a 50-year-old woman who presents to the ED with progressive neurologic symptoms and is admitted to the neurology service. Test your diagnostic and therapeutic skills at NEJM.org.
- N Engl J Med 2022; 387:421-432
Prasinezumab is a monoclonal antibody to α-synuclein, a protein involved in the pathogenesis of Parkinson’s disease. In a placebo-controlled trial, prasinezumab did not slow the progression of disease over a period of 52 weeks.
- N Engl J Med 2022; 387:408-420
In a phase 2 trial in early Parkinson’s disease, treatment with cinpanemab, a monoclonal antibody to α-synuclein, did not affect clinical or imaging progression over a period of 72 weeks.
- N Engl J Med 2022; 387:466-467
Parkinson’s disease is increasing in incidence at a faster rate than any other serious neurologic condition.1 Despite multiple agents putatively showing preclinical promise, there is no disease-modifying therapy available for clinical use in this disorder. Indeed, no potential treatment has survived scrutiny in a clinical trial to reach...
- N Engl J Med 2022; 387:e7
A 23-year-old man presented with double vision and eyelid drooping on the right side that worsened at the end of the day. The neurologic examination showed ptosis on the right side and “curtain sign” (as seen in a video).
- N Engl J Med 2022; 387:e5
A 78-year-old man with type 2 diabetes presented with hemiballism of the left arm and leg (shown in a video). Evaluation revealed hyperglycemia and an area of increased density in the right basal ganglia on imaging.
- N Engl J Med 2022; 387:148-159
In this multicenter, randomized trial, the administration of erythropoietin to newborns undergoing therapeutic hypothermia for hypoxic–ischemic encephalopathy did not result in a lower risk of death or neurodevelopmental impairment at 22 to 36 months of age than placebo and was associated with a higher rate of serious adverse events.
- N Engl J Med 2022; 386:2508-2516
A 25-year-old man with a history of leukemia and hematopoietic-cell transplantation was evaluated for vision changes. MRI revealed white-matter lesions; PET-CT showed FDG-avid lymphadenopathy. A diagnostic test was performed.
- N Engl J Med 2022; 386:2471-2481
A total of 12 pediatric patients with diffuse intrinsic pontine glioma were treated with a direct infusion of an oncolytic virus, followed by radiotherapy. The tumor size was reduced in 9 patients, and disease was stable over a median follow-up of 18 months in 8 patients.